此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Continuous Antibiotic Infusion In Children

2026年5月4日 更新者:Tampere University Hospital

Continuous intravenous antibiotic infusion using elastomeric pumps is well established in adult care and has been shown to be effective, safe, and cost-efficient, particularly for beta-lactams and vancomycin. In pediatric outpatient parenteral antimicrobial therapy (p-OPAT), home intravenous treatment is feasible and safe, improves quality of life, and reduces hospital stays and healthcare-associated infections. Elastomeric pumps offer practical advantages, including portability, ease of use, fixed infusion rates, and reduced drug handling, although they are limited by fixed flow rates and drug stability.

This prospective study at Tampere University Hospital (Tays) will evaluate the safety and cost-effectiveness of 24-hour continuous antibiotic infusions in children between January 2026 and January 2029. Eligible pediatric patients requiring intravenous antimicrobial treatment and suitable for home care will be included. Indications include serious bacterial infections such as bacteremia, osteomyelitis, septic arthritis, neutropenic fever, cystic fibrosis-related infections, and foreign body infections. The study antibiotics are benzylpenicillin, cloxacillin, piperacillin/tazobactam, and vancomycin, administered via CE-approved infusion devices for home use.

Children will receive continuous infusion either initially in hospital or directly from the emergency department if appropriate, with treatment duration and dosing comparable to standard intermittent regimens. Outcomes include safety, feasibility, cost-effectiveness, and patient-reported quality of life measured using PedsQL™. The study aims to determine whether continuous infusion can optimize pediatric antimicrobial care and healthcare resource utilization. Results will be published in peer-reviewed international journals.

研究概览

地位

招聘中

条件

详细说明

Continuous antibiotic infusion has long been used in adults, administered via elastomeric devices.

The most used antibiotics are beta-lactams (benzylpenicillin, cloxacillin, piperacillin-tazobactam) and glycopeptides (vancomycin), and these are also in use in adults' home hospital unit at Tampere University Hospital (Tays). Several studies have found that beta-lactam antibiotics are as effective or even more effective when administered as a continuous infusion compared to intermittent infusions. Continuous infusion via an elastomeric pump has been found to be safe in adult outpatient care. Intravenous antibiotic therapy at home for children (paediatric outpatient parenteral antimicrobial therapy, p-OPAT) has been found to be both feasible and safe. It has been shown to increase parental and patient satisfaction, mental well-being, and return to school, as well as reduce healthcare-associated infections and bring cost savings. In previous publications from pediatric population, continuous antibiotic infusion via an elastomeric device have shown to be safe. Elastomeric pumps have found to have many benefits.

They are disposable, portable, lightweight, closed, and pre-filled, reducing drug handling. Pumps have a constant rate, preventing programming errors, and are relatively inexpensive (depending on the drug cost). The disadvantages are that the pumps are in the fixed size and flow rate of the device, the need for pharmacy involvement for each fill, and the choice of antimicrobial therapy being dependent on drug stability. Prolonged and continuous antibiotic infusions have shown a greater probability of reaching targeted antimicrobial levels compared to intermittent infusion regimens, and generally have good clinical outcomes, tolerability, and safety profile. They also have cost benefits and may reduce the length of hospitalization in adults. The aim of this study is to investigate continuous (24h) antibiotic infusions in children at Tays and aims to study the cost-effectiveness and safety of continuous antibiotic infusions via elastomeric pump or another suitable infusion device. The study will prospectively include children treated at Tampere University Hospital with antimicrobial treatment requiring intravenous administration and suitable for infusion via elastomeric pump. Such patients could include for example patients with neutropenic fever, osteomyelitis, septic arthritis, infections with positive blood culture/bacteremia, patients with cystic fibrosis or foreign body infections. Other children who meet the criteria for suitable intravenous antibiotic treatment will also be included. The antibiotics used in the study are benzylpenicillin, cloxacillin, piperacillin/tazobactam and vancomycin. Patients are recruited during the next three years 01/2026-01/2029. The children included in the study are treated with continuous antibiotic infusion and are suitable for home care the same way as the patients with intermittent antibiotic infusion. Antibiotic treatment will be administered as a 24-hour continuous infusion. The first two patients in each antibiotic group will receive continuous infusion treatment in the ward at the beginning of the infusion, and if the treatment proceeds without problems, it will continue at home. Later, patients may receive antimicrobial treatment via elastomeric pump at first-line treatment in the emergency room or patients with antimicrobial 5 treatment administered as boluses can be transmitted for elastomeric pump. The duration of antibiotic treatment and used antimicrobe will be the same as for intermittent infusions administered several times per day in hospital. Antibiotic dosage depends on several factors, such as the child's weight, age, the type and site of infection, severity of infection, patient's medical history, local resistance patterns and the causative bacterium. Children admitted to the ward with intermittent antibiotic treatment requiring prolonged intravenous treatment may also be recruited for the study, if continuous antimicrobial treatment is estimated as beneficial. Prolonged intravenous treatment is defined as well-being child with only reason to continue treatment in hospital ward is the need of intravenous antimicrobial treatment (no other surveillance, ventilation support etc) The study will be performed in the pediatric ward, pediatric emergency department and pediatric home hospital of The Wellbeing Services County of Pirkanmaa (Pirha). In the study, continuous antibiotic infusion will be via an elastomeric pump (Baxter), CADD-Solis VIP infusion device, or another suitable infusion device. The study uses only CE-marked infusion pumps that, according to the manufacturer's stated intended use, are approved for home use in children In Finland, continuous antibiotic infusions are already used to some extent in children in various hospitals, but to our knowledge, no research has been conducted in the Nordic countries and none including the cost-effectiveness. Continuous antibiotic infusion allows children to stay at home instead of in the hospital in certain situations. The investigators will assess the perceived quality of life of children using a validated quality of life questionnaire PedsQLTM. The aim is to determine whether the use of continuous antibiotic infusions could be cost-effective and thus optimize healthcare resources.

Reports from the sub-studies will be prepared and submitted for publication in an international peer-reviewed medical journal.

研究类型

介入性

注册 (估计的)

150

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Tampere、芬兰、33520
        • 招聘中
        • Pediatric Early Phase Trials Unit (PeeTU), Tampere University Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子

接受健康志愿者

不

描述

Inclusion Criteria:

  • iv-antibiotic treatment is necessary
  • clinically stable
  • no need to stay in hospital
  • pump or cassette can be changed at the hospital or at home
  • care givers are able to contact hospital if needed
  • clinical diagnose is not uncertain
  • no allergy for the used antibiotic
  • the continuous antibiotic infusion hasn't been started yet or it has been initiated no more than 24 hours prior to study enrolment

Exclusion Criteria:

  • the pump cannot be carried with the child
  • the child must stay at the hospital for monitoring or other reason
  • unclear diagnose

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Continuous antibiotic infusion
Different antibiotics will be used according to the condition being treated
其他名称:
  • 哌拉西林他唑巴坦
  • 氯唑西林
  • vancomysin

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Cost of treatment
大体时间:From hospitalization to the end of the continuous antibiotic infusion
Total treatment cost
From hospitalization to the end of the continuous antibiotic infusion
Duration of fever
大体时间:From the beginning of the disease to the end of the continuous antibiotic infusion
Number of days from antibiotic initiation to resolution of fever
From the beginning of the disease to the end of the continuous antibiotic infusion
Change in C-reactive protein (CRP) mg/ml
大体时间:From hospitalization to the end of the continuous antibiotic infusion
Number of days from antibiotic initiation to normalization of values. Blood test are taken from all patiens D1 and D3
From hospitalization to the end of the continuous antibiotic infusion
Concomitant medications
大体时间:From hospitalization to the end of the continuous antibiotic infusion
Time from antibiotic initiation to discontinuation of pain/fever medications or other supportive drugs
From hospitalization to the end of the continuous antibiotic infusion
Parental absence from work (in days)
大体时间:From hospitalization to the end of the continuous antibiotic infusion
From hospitalization to the end of the continuous antibiotic infusion
Distance from home to hospital (in kilometers)
大体时间:In the beginning of the study
Geographic coverage of care
In the beginning of the study
Duration of antibiotic treatment (in days)
大体时间:From hospitalization to the end of the continuous antibiotic infusion, up to one month
Total duration including inpatient treatment and duration of continuous outpatient antibiotic therapy
From hospitalization to the end of the continuous antibiotic infusion, up to one month
Safety, measured with adverse events
大体时间:Assessed from study initiation up to three months thereafter
Assessed from study initiation up to three months thereafter
Emergency or clinic visits
大体时间:Assessed from discontinuation of continuous antibiotic infusion up to one month thereafter
Assessed from discontinuation of continuous antibiotic infusion up to one month thereafter

次要结果测量

结果测量
措施说明
大体时间
: The incidence of IV route problems
大体时间:From the beginning of continuous antibiotic infusion to the end of the continuous antibiotic infusion, up to one month
From the beginning of continuous antibiotic infusion to the end of the continuous antibiotic infusion, up to one month
Quality of life of children assessed by PedsQL
大体时间:At the enrollment, at the discontinuation of continuous antibiotic infusion and at the follow up visit (30 days +/- 3 days from the discontinuation of antibiotic infusion)
The questionnaire include scores of Physical Functioning, Emotional Functioning, Social Functioning, School Functioning, Total score, Psychosocial health summary score and Physical health summary score. Scores are transformed on a scale from 0 to 100. Higher scores means better Healt-Related Quality of Life.
At the enrollment, at the discontinuation of continuous antibiotic infusion and at the follow up visit (30 days +/- 3 days from the discontinuation of antibiotic infusion)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月21日

初级完成 (估计的)

2028年12月31日

研究完成 (估计的)

2031年12月31日

研究注册日期

首次提交

2026年4月22日

首先提交符合 QC 标准的

2026年5月4日

首次发布 (实际的)

2026年5月8日

研究记录更新

最后更新发布 (实际的)

2026年5月8日

上次提交的符合 QC 标准的更新

2026年5月4日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Pseudonymized data will be provided upon reasonable request

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅